Directory Calendar Careers Alumni Giving

Amy L Hartman, PhD

Assistant Professor, Infectious Diseases and Microbiology

Research Manager, Regional Biocontainment Laboratory, Center for Vaccine Research


BST3, 3501 Fifth Ave., Pittsburgh, PA 15261
R-znvy: unegzna7@cvgg.rqh
Primary Phone: 967-193-3210
Fax: 967-193-3462

Personal Statement

Dr. Hartman received her bachelor's degree in Biology from Washington and Jefferson College in 1998. She received her Ph.D. in Molecular Virology from the Department of Molecular Genetics and Biochemistry at the University of Pittsburgh School of Medicine in 2003. Her graduate thesis was done in the laboratory of Mickey Murphey-Corb, Ph.D. and focused on host factors controlling Simian Immunodeficiency Virus (SIV) infection in rhesus macaques.

Dr. Hartman then did a post-doctoral fellowship in the Special Pathogens Branch at the Centers for Disease Control and Prevention in Atlanta, GA under Stuart Nichol, Ph.D. Her work focused on viral virulence factors contributing to severe disease induced by infection with Ebola Zaire virus. During her time at CDC, Dr. Hartman was a member of the outbreak response team sent to Angola in 2005 during the largest recorded outbreak of Marburg Hemorrhagic Fever.  Dr. Hartman assisted with setup and operation of the molecular diagnostic laboratory, which used Taqman PCR to diagnose patient clinical samples.  

Dr. Hartman returned to the University of Pittsburgh in 2007 as the Research Manager of the Regional Biocontainment Laboratory with a primary faculty appointment in the Department of Infectious Disease and Microbiology (IDM) in the Graduate School of Public Health (GSPH).


1998 | Washington and Jefferson College, Washington, PA | BA
2003 | University of Pittsburgh School of Medicine, Pittsburgh, PA | PhD 


Course Director:  
IDM2004 - Viral Pathogenesis


IDM 2002 - Molecular Virology

IDM 2003 - Host Response to Microbial Infection

IDM 2010 - Pathogen Biology

IDM 2038 - Prevention, Treatment, and Control of Global Infectious Diseases

MSMVM 3440 - Vaccines and Immunity 


The Hartman lab is seeking motivated post-doctoral scholars with an interest in the neuropathogenesis of arboviruses. Candidates will need to pass Department of Justice clearance and the University of Pittsburgh’s Tier 1 Select Agent Suitability Assessment.  Successful applicant must be willing to work in BSL-3/ABSL-3 and undergo a rigorous safety training program. Entry-level or experienced post-docs are encouraged to apply. Interested candidates should email a CV and cover letter.  

Research Interests

Dr. Hartman's broad research interests center on understanding the pathogenic mechanisms of RNA viruses, particularly arboviruses (viruses transmitted by insect vectors).  The focus of her research is on arboviruses that have the potential to spread to new locations (emerging viruses), as well as those that have the potential for misuse through bioterrorism.  In addition to understanding the disease-causing mechanisms of these viruses, Dr. Hartman works closely with the Department of Defense to assist in the testing of new treatments and vaccines to protect U.S. military personnel from exposure to virulent viruses.  Current research projects in Dr. Hartman's lab focus on aerosol infection models of Rift Valley Fever virus and the alphaviruses (Eastern, Western, and Venezuelan equine encephalitis viruses).

Rift Valley Fever virus (RVFV) is a mosquito-borne virus that causes severe disease in livestock and humans in Africa and the Arabian peninsula. Rift Valley Fever is found endemically in these regions, and rainfall alterations can lead to epizootics in livestock and epidemics in humans. RVFV is easily transmitted when humans handle infected animal carcasses, and this transmission is thought to be by mucosal exposure or direct inhalation of virus particles. Due to its ability to infect by the aerosol route, RVFV is also considered a potential bioterror threat. For these reasons, better vaccines and therapeutics for this globally-important emerging infectious disease are needed. 

The World Health Organization published a list of the emerging pathogens likely to cause major epidemics in the near future, including Rift Valley Fever.  In January of 2016, Science magazine named Rift Valley Fever as one of the top 10 diseases for which a vaccine is urgently needed.


Current research projects in Dr. Hartman's lab focus on the neuropathogenesis of RVFV. Dr. Hartman has established the first well-characterized models of the neurological disease that is seen in some RVFV-infected people. These models are currently being used to understand how the virus causes lethal encephalitis. Dr. Hartman's models have also been used to test novel antiviral drugs, such as Favipiravir (T-705), to determine its broad-spectrum applicability to treat emerging diseases. 

Dr. Hartman's lab at the University of Pittsburgh Regional Biocontainment Laboratory has the necessary federal approvals to work at BSL-3, advanced equipment, and trained staff to successfully implement large research grants and contracts aimed at understanding the pathogenesis of infectious diseases.

Lab Members


Cynthia McMillen, PhD (post-doc)

Aaron Walters, MS (Research Technician)

Michael Kujawa, MS (PhD student)
Noah Salama (MS student)

Joseph Albe (MPH-PEL student)

Tiffany Thompson (MPH-PEL student)

Stacey Barrick (Project Coordinator)

Jeneveve Lundy (Veterinary Technician)

Past Staff:
Jacquelyn M. Bales (Research Technician)
Diana Powell (Veterinary Technician)
Laura Bethel (Research Technician)

Past Students:
Aaron Walters - MS degree awarded December 2016. Thesis: "The effect of infection route on disease outcome in rats infected with Rift Valley fever virus."


Michael Kujawa - MS degree awarded April 2016.  Thesis: "Understanding the neuropathogenesis of Rift Valley Fever using in vitro and in vivo models."


Jonathan Berback - MPH-PEL degree awarded December 2015.  Thesis: "Antiviral activity of primary human trophoblast conditioned media against Rift Valley Fever virus."


David Jung - MPH-PEL degree awarded December 2015.  Thesis: "Efficacy and Cytotoxicity of Novel Antiviral Compounds Against Rift Valley Fever Virus."


Amy L. Caroline - MS degree awarded April 2013.  Thesis: "Characterization of the humoral immune response in rats and non-human primates exposed to aerosolized virulent Rift Valley Fever virus."

Outbreak and Field Experience

Time Period




April – May 2005

Marbug Hemorrhagic Fever

Luanda, Angola

1. Worked as a team to establish a safe field laboratory for work with high-hazard BSL-4 viruses in a third-world setting under extreme conditions.

2. Ran the diagnostic molecular biology laboratory which used a real-time Taqman PCR assay to diagnose blood, serum, and swab specimens from suspected cases of Marburg Hemorrhagic Fever.

3. Analyzed data, monitored quality control standards, and reported case results to the Ministry of Health and World Health Organization.


February – March 2007

Rift Valley Fever (Kenya)

Atlanta, GA

Provided laboratory support for team deployed in Nairobi, Kenya. Performed RT-PCR amplification and genome sequencing of veterinary specimens obtained by field laboratory.

Professional Memberships

American Society for Microbiology (ASM)

American Society for Virology (ASV)

American Biological Safety Association (ABSA)

American Society of Tropical Medicine and Hygeine (ASTMH)

American Committee on Arthropod-borne viruses (ACAV)

International Society for NeuroVirology

Selected Publications

Full list of publications through My NCBI.

ORCID: 0000-0002-0857-2973

Scopus Author ID: 7102651927

Google Scholar

Most recent listed first:
Wonderlich, E.R., Z.D Swan, S.J. Bissel, A.L. Hartman, J.P. Carney, K.J.
O’Malley, A.O. Obadan, J. Santos,, R. Walker, T.J. Sturgeon, L.J. Frye Jr, P.
Maiello, C.A. Scanga, J.D. Bowling, A.L. Bouwer, P.A. Duangkhae, C.A. Wiley, J.L. Flynn, J. Wang, K.S. Cole, D.R. Perez, D.S. Reed, and S.M. Barratt-Boyes. 2017. Widespread virus replication in alveoli drives acute respiratory distress syndrome in aerosolized H5N1 influenza infection of macaques. Journal of Immunology. 198. DOI:

Caroline, A.L., M.R. Kujawa, T. Oury, D.S. Reed, and A.L. Hartman.  2016.  Inflammatory biomarkers associated with lethal Rift Valley fever encephalitis in the Lewis rat model.  Frontiers in Microbiology.  6:1509.  DOI:10.3389/fmicb.2015.01509.  

Mirza, S.K., T.R. Tragon, M.B. Fukui, M.S. Hartman, and A.L. Hartman.  2015. Microbiology for Radiologists: How to Minimize Infection Transmission in the Radiology Department.  RadioGraphics.  45(4). DOI:

Caroline, A.L., D.S. Powell, L.M. Bethel, T.D. Oury, D.S. Reed, and A.L. Hartman.  2014. Broad spectrum antiviral activity of Favipiravir (T-705): Protection from highly lethal inhalational Rift Valley Fever.  PLOS Neglected Tropical Diseases. 8(4):e2790. DOI:10.1371/journal.pntd.0002790.
Reed, D.S., Bethel, L.M., Powell, D.S., A.L. Hartman. 2014.  Differences in aerosolization of Rift Valley Fever virus resulting from choice of inhalation exposure chamber: implications for animal challenge studies. Pathogens & Disease. DOI:10.1111/2049-632X.12157.
Powell, D.S., R.C. Walker, D.T. Heflin, D. Fisher, J.B. Kosky, L.C. Homer, D.S. Reed, K.S. Cole, A.M. Trichel, and A.L. Hartman.  2014. Development of novel mechanisms for housing, handling, and remote monitoring of common marmosets at animal biosafety level 3.  Pathogens & Disease.  DOI: 10.1111/2049-632X.12140.
Hartman, A.L., Powell, D.S., Bethel, L.M., Caroline, A.L., Schmid, R.J., Oury, T., and Reed, D.S.
2014. Aerosolized Rift Valley Fever virus causes fatal encephalitis in African green monkeys and common marmosets. Journal of Virology 88(4):2235-2245. DOI: 10.1128/JVI.02341-13.
6.  Narayanan, A., K. Kehn-Hall, S. Senina, L. Lundberg, R. Van Duyne, I. Guendel, R. Das, A. Baer, L. Bethel, M. Turell, A.L. Hartman, B. Das, M.S. Navati, A.J. Friedman, J.M. Friedman, C. Bailey, and F. Kashanchi.  2012.  Curcumin inhibits Rift Valley Fever Virus replication in human cells.  Journal of Biological Chemistry.  287(40):33198-33214.

Bales, J.M., D.S. Powell, L.M. Bethel, D.S. Reed, and A.L.Hartman.  2012. Choice of inbred rat strain impacts lethality and disease course after respiratory infection with Rift Valley Fever Virus.  Frontiers in Cellular Infection Microbiology.  2(105):1-14. 

Hartman, A.L., K.S. Cole, and L.C. Homer.  2012.  Verification of Inactivation Methods for Removal of Biological Materials from a Biosafety Level-3 Select Agent Facility.  Applied Biosafety: Journal of the American Biological Safety Association.  17(2):70-75. 

Homer, L.C., A.L.Hartman, D.T. Heflin, A.M. Trichel, D.S. Reed, and K.S. Cole.  2011.  Enhancement of the Mentored Training Program for Investigative Staff at the University of Pittsburgh Regional Biocontainment Laboratory.  Applied Biosafety: Journal of the American Biological Safety Association.  16(4):231-239.

Hartman, A.L., L.C. Homer, A.M. Trichel, D. Fisher, J. Frerotte, and K.S. Cole.  2010. Evolution of a Facility-Specific BSL-3 Training Program for the University of Pittsburgh Regional Biocontainment Laboratory.  Applied Biosafety: Journal of the American Biological Safety Association.  15(3):137-141.

Bird, B.H., J. Githinji, J. Macharia, J. Kasiiti, R.M. Muriithi, S.G. Gacheru, J.O. Musaa, J.S. Towner, S.A. Reeder, J.B. Oliver, T.L. Stevens, B.R. Erickson, L.T. Morgan, M.L. Khristova, A.L. Hartman, J.A. Comer, P.E. Rollin, T.G. Ksiazek, and S.T. Nichol. 2008.  Multiple virus lineages sharing recent common ancestry were associated with a large Rift Valley fever outbreak among livestock in Kenya during 2006-2007.  Journal of Virology 82(22):11152 - 11166.

Hartman, A.L., L. Ling, S.T. Nichol, and M.L. Hibberd. 2008.  Whole Genome Expression Profiling Reveals that Inhibition of the Host Innate Immune Response by Ebola Virus can be Reversed by a Single Amino Acid Change in the VP35 Protein. Journal of Virology 82(11): 5348-5358.

Hartman, A.L., B.H. Bird, J.S. Towner, Z. Antoniadou, S. Zaki, and S.T. Nichol.  2008.  Inhibition of IRF-3 activation by VP35 is critical for the high virulence of Ebola virus. Journal of Virology 82(6):2699-2704.

Bird, B.H., C. Albarino, A.L. Hartman, B. Erickson, T. Ksiazek, and S.T. Nichol. 2008.  Rift Valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from
virulent virus challenge, and allows for differential identification of infected and vaccinated animals. Journal of Virology 82(6):2681-2691.

Hartman, A. L., J. E. Dover, J. S. Towner, and S. T. Nichol.  2006.  Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication.  Journal of Virology. 80(13):6430-6440.

Towner, J. S., M. L. Khristova, M. Vincent, T. K. Sealy, B. R. Erickson, D. Bawiec, A L. Hartman, A. Comer, S. Zaki, H. Feldmann, P. Rollin, T. G. Ksiazek, and S. T. Nichol.  2006.  Emergence of Marburg Virus in Angola, West Africa. Journal of Virology. 80(13):6497-6516.

Cárdenas, W. B., Y.-M. Loo, M. Gale Jr., A. L. Hartman, and C. F. Basler.  2006.  Ebola virus VP35 protein binds dsRNA and inhibits interferon α/β production induced by RIG-I signaling. Journal of Virology.  80(11):5168-78.

Reid, S.R., L. W. Leung, A. L. Hartman, O. Martinez, M. L. Shaw, C. Carbonnelle, V. E. Volchkov, S. T. Nichol, and C. F. Basler.  2006.  Ebola virus VP24 Binds Karyopherin-alpha1 and Blocks STAT1 Nuclear Accumulation.  Journal of Virology.  80(11):5156-67.

Hartman, A. L., J. S. Towner, and S. T. Nichol.  2004.  A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus.  Virology. 328:177-184.

Amy L Hartman
© 2017 by University of Pittsburgh Graduate School of Public Health

Login  |  Sitemap